The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Optimal sequencing strategies in molecularly-driven CRC
Dominik Modest, MD, Charité – Universitätsmedizin Berlin, Berlin, Germany, gives an overview of treatment strategies for colorectal cancer with driver mutations. Immune checkpoint inhibitors are the standard of care for microsatellite instability (MSI) high colorectal cancer, whereas BRAF and EGFR inhibitors are used for BRAF-mutant colorectal cancer in the first and second line settings respectively. In Europe, off-label therapies are recommended for HER2-mutated colorectal cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
